MGC Pharma hits key milestone as prescription growth accelerates for its medicinal cannabis drugs
Health & Biotech
Health & Biotech
Link copied to
Special Report: More than 200 prescriptions in the UK and Australia have now been issued for MGC Pharma’s medicinal cannabis products CannEpil and MXP100.
MGC Pharma (ASX:MXC) has increased the number of patients accessing its medicines, as it hits a key milestone for prescriptions written and filled in the UK and Australia.
The seed-to-pharmacy bio-pharma company has two products, epilepsy treatment CannEpil and 100mg/mL cannabidiol drug MXP100, being prescribed, either through the Special Access Scheme in Australia or in the UK under the Early Access to Medicines Scheme.
And in the past month alone, more than 100 patients in both jurisdictions have accessed the products, demonstrating the company’s proprietary standardised, affordable medicines and its increasing distribution capabilities.
They are manufactured at the company’s European facilities. They are then distributed via MGC Pharma’s distribution partners, Cannvalate and Health House in Australia, and Grow Biotech in the UK.
MGC also revealed that its products have been recently on-boarded by Tetra Health and Cannabis Access Clinics into their catalogue of available products provided to their networks of medical professionals, boosting their distribution in Australia.
Roby Zomer, co-founder and managing director, said the milestone was validation of the company’s business model.
“Having progressed CannEpil and MXP100 from the research and development stages through to commercialisation, we now have a proven process in which we can advance additional standardised, affordable phytocannabinoid derived medicines,” he said.
“Critically, with our unique EU-GMP production and key market distribution infrastructure now established, we can meet this increasing demand for our offering of phytocannabinoid derived medicines in our existing and future markets.
“We anticipate the uptake of patients to continue to increase accordingly, providing revenue to invest further in new production and our research & development strategies, as well as cementing MGC Pharma has a key player in the medical cannabis sector globally.”